Search results
Results from the WOW.Com Content Network
Tinzaparin is an antithrombotic drug in the heparin group. It is a low molecular weight heparin (LMWH) marketed as Innohep worldwide. It has been approved by the U.S. Food and Drug Administration (FDA) for once daily treatment and prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE).
The range and occurrence of adverse effects are similar for all of the PPIs, though they have been reported more frequently with omeprazole. This may be due to its longer availability and, hence, clinical experience. [citation needed] Common adverse effects include headache, nausea, diarrhea, abdominal pain, fatigue, and dizziness. [30]
The medication is applied to the skin. [1] Besides its use in medicine, tapinarof is a naturally occurring compound found in bacterial symbionts of nematodes which has antibiotic properties. [2] [3] The medication acts as an aryl hydrocarbon receptor agonist. [1] [4] Tapinarof was approved for medical use in the United States in May 2022.
The most prevalent side effects include nausea, mild sedation, fatigue, and dizziness. At higher dosages, there is an increased risk for restlessness, insomnia, and tremors. [6] Cariprazine was approved for medical use in the United States in September 2015. [12] It was approved as a generic medication in 2022, [13] but is covered by patents ...
It interacts with many medications, including other mood stabilizers (e.g. lamotrigine) and antipsychotics (e.g. quetiapine). [12] It is considered second-line for bipolar disorder due to its side effects. [13] There is insufficient evidence to support the use of various other anticonvulsants, such as gabapentin and topiramate, as mood ...
Mirtazapine, sold under the brand name Remeron among others, is an atypical tetracyclic antidepressant, and as such is used primarily to treat depression. [11] [12] Its effects may take up to four weeks but can also manifest as early as one to two weeks.
Side effects of midodrine include hypertension (high blood pressure), paresthesia, itching, goosebumps, chills, urinary urgency, urinary retention, and urinary frequency. [3] Midodrine is a prodrug of its active metabolite desglymidodrine. [3] [1] This metabolite acts as a selective agonist of the α 1-adrenergic receptor.
The drug acts more slowly than older dihydropyridines. [citation needed] It probably has fewer adverse effects, but a comparatively high potential for drug interactions. It was patented in 1984 and first approved for medical use in 1997. [2] The US FDA refused to approve the drug, and lercanidipine is not marketed in USA. [3]